<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2095">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133895</url>
  </required_header>
  <id_info>
    <org_study_id>Tocilizumab treatment on IRPF</org_study_id>
    <nct_id>NCT05133895</nct_id>
  </id_info>
  <brief_title>The Effect and Safety of Tocilizumab Treatment on IRPF</brief_title>
  <official_title>A Prospective Study of Tocilizumab Treatment on Idiopathic Retroperitoneal Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to investigate the treatment response of Tocilizumab on patients&#xD;
      with idiopathic retroperitoneal fibrosis（IRPF）.&#xD;
&#xD;
      Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF&#xD;
      patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months.&#xD;
&#xD;
      Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF&#xD;
      patients; the secondary endpoints include the decrease of inflammatory markers, side effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 3 months</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Idiopathic Retroperitoneal Fibrosis</condition>
  <condition>Tocilizumab Treatment</condition>
  <arm_group>
    <arm_group_label>Tocilizumab treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab treatment</intervention_name>
    <description>Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month.</description>
    <arm_group_label>Tocilizumab treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone Monotherapy</intervention_name>
    <description>Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.</description>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adults, ≥ 18 years of age at time of informed consent;&#xD;
&#xD;
          2. Written informed consent;&#xD;
&#xD;
          3. Diagnosed with retroperitoneal fibrosis and normal level of Serum IgG4;&#xD;
&#xD;
          4. Higher level of ESR and CRP than normal;&#xD;
&#xD;
          5. Pathologic results show fibrosis and IgG4/IgG &lt;50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Combined with other connective tissue disease.&#xD;
&#xD;
          2. Known immunodeficiency disorder.&#xD;
&#xD;
          3. Active malignancy or history of malignancy that was active within the last 10 years.&#xD;
&#xD;
          4. Pregnancy, lactation, or planning to become pregnant within 6 months of the test.&#xD;
&#xD;
          5. Positive test for, or prior treatment for, hepatitis B or HIV infection. A positive&#xD;
             test for hepatitis B is detection of hepatitis B surface antigen (HBsAg) or HBV-DNA.&#xD;
&#xD;
          6. Evidence of active tuberculosis (TB), including Chest X-ray and PPD.&#xD;
&#xD;
          7. Severe abnormal liver function or cardiac insufficiency.&#xD;
&#xD;
          8. Any reason the investigator think that should not attend this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunyun Fei</last_name>
    <phone>+8613681125226</phone>
    <email>feiyunyun2013@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yunyun Fei</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunyun Fei</last_name>
      <phone>+8613681125226</phone>
      <email>feiyunyun2013@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>idiopathic retroperitoneal fibrosis</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Retroperitoneal Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

